App-Quantinova.ai

Non‐invasive stratification of fatty liver disease with high‐throughput multiparametric MRI

Matthew D. Kelly - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Fatty Liver Disease

N/A

High‐throughput RNA sequencing on liver biopsy material stratifies patients with non‐alcoholic fatty liver disease

Olivier Govaere - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Fatty Liver Disease

N/A

Liver fibrosis as assessed by the FIB‐4 index and metabolic markers in subjects with type 2 Diabetes

Claudia M. Filozof - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Fatty Liver Disease

N/A

Improvement in Hepatic Transaminases Over 12 Months After Single Procedure Duodenal Mucosal Resurfacing in Type 2 Diabetes Patients

Annieke van Baar - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Type 2 diabetes mellitus

N/A

Comparison of published noninvasive biomarkers to reliably exclude severe fibrosis in NAFLD patients

Peter J. Eddowes - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Nonalcoholic fatty liver disease

N/A

Insulin secretion and decreased glucose clearance are associated with enhanced fibrogen‐ esis and a high risk of disease progression in non‐diabetic patients with Non Alcoholic Fatty Liver Disease

Ramy Younes - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Fatty Liver Disease

N/A

Nonalcoholic Steatohepatitis (NASH) Impairs Ventricular Diastolic Distensibility And Function Independent Of Underlying Type 2 Diabetes Or Hypertension

Mohammad Siddiqui - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Nonalcoholic steatohepatitis

N/A

Effect of semaglutide on alanine aminotransferase in subjects with type 2 diabetes and high cardiovascular risk

Arun J. Sanyal - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Chronic kidney disease

Semaglutide

Development of an algorithm for the prediction of cardiovascular events in patients with NAFLD: the role of mean platelet volume

Benjamin Mullish - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Transient Ischemic Attack

N/A

Comparison of Sonic Hedgehog and keratin 8/18 immunostains as markers of ballooned hepatocytes in non‐alcoholic fatty liver disease (NAFLD)

Dina G. Tiniakos - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Fatty Liver Disease

N/A

Understanding the Patient‐Perceived Impact of Nonalcoholic Steatohepatitis: Raising the Volume on a Silent Disease

Lynda C. Doward - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Nonalcoholic steatohepatitis

N/A

Patterns and Outcomes of Thoracic Organ Transplantation Across Citizenship Status in the United Status

Lauren Sinnenberg - American Heart Association (AHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Effect of Dapagliflozin According to Duration of Heart Failure: An Analysis of the DAPA-HF Trial

Su E Yeoh - American Heart Association (AHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

Dapagliflozin

Dynamic Device Derived Heart Failure Risk Score as a Predictor of Heart Failure Hospitalisation

Maciej Debski - American Heart Association (AHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

N/A

Risk Prediction in Chronic Heart Failure: Comparison of the PREDICT-HF and MAGGIC Risk Scores in 4744 Patients in DAPA-HF

JoAnne Simpson - American Heart Association (AHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

N/A

Sacubitril/valsartan as a Treatment for Resistant Hypertension in Patients With Heart Failure and Preserved Ejection Fraction

Pardeep S Jhund - American Heart Association (AHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Hypertension

Sacubitril/valsartan

Serum Potassium and Risk of Death in Patients With HFpEF: An Analysis of PARAGON-HF

Joao Ferreira - American Heart Association (AHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Heart failure with preserved ejection fraction

N/A

Myocardial Regeneration in End-stage Heart Failure After Left Ventricular Unloading

Tiberiu Pana - American Heart Association (AHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Advanced heart failure

N/A

Exercise Left Ventricular Ejection Fraction Predicts Long-term Brain Natriuretic Peptide Levels in Patients Undergoing Surgery for Severe Secondary Ischemic Mitral Regurgitation

Carlo Fino - American Heart Association (AHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Ischemic mitral regurgitation

N/A

Predicting Out-of-office Blood Pressure in United States Adults

Brandon K Bellows - American Heart Association (AHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Masked hypertension

N/A

Filters

45280 Abstracts